What one share of BridgeBio Oncology Therapeutics holds
BBOT is a clinical-stage biotechnology company with the mission of transforming the lives of patients with cancers driven by RAS and PI3Kα, the two most frequently mutated oncogenes. Aberrant RAS signaling drives uncontrolled tumor growth in some of the deadliest cancers, including lung, breast, pancreas and colon cancer.
BridgeBio Oncology Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.69 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$3.07 |
| Cash and investments | $4.30 |
| Book value | $4.03 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2025 | — | −$4.30 | $0.02 | −$3.68 | — | $5.14 |
Common questions about BridgeBio Oncology Therapeutics
How much does one share of BridgeBio Oncology Therapeutics earn?
Over the last 12 months, BridgeBio Oncology Therapeutics lost $3.69 for each share.
Does BridgeBio Oncology Therapeutics pay a dividend?
BridgeBio Oncology Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is BridgeBio Oncology Therapeutics’s book value per share?
BridgeBio Oncology Therapeutics’s book value is $4.03 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of BridgeBio Oncology Therapeutics have?
Each share of BridgeBio Oncology Therapeutics has $4.30 of cash and investments, as of June 30, 2026.
What is BridgeBio Oncology Therapeutics’s free cash flow per share?
−$3.07 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.